Prostaglandin E synthase: a novel drug target for inflammation and cancer

Current Pharmaceutical Design
Makoto Murakami, Ichiro Kudo

Abstract

Prostaglandin E synthase (PGES), which converts cyclooxygenase (COX)-derived prostaglandin (PG) H(2) to PGE(2), occurs in multiple forms with distinct enzymatic properties, modes of expression, cellular and subcellular localizations and intracellular functions. Two of them are membrane-bound enzymes and have been designated as mPGES-1 and mPGES-2. mPGES-1 is a perinuclear protein belonging to the MAPEG (for membrane-associated proteins involved in eicosanoid and GSH metabolism) family. This enzyme is markedly induced by proinflammatory stimuli, is down-regulated by anti-inflammatory glucocorticoids, and is functionally coupled with cyclooxygenase (COX)-2 in marked preference to COX-1. mPGES-2 is synthesized as a Golgi membrane-associated protein, and the proteolytic removal of the N-terminal hydrophobic domain leads to the formation of a mature cytosolic enzyme. This enzyme is rather constitutively expressed in various cells and tissues and is functionally coupled with both COX-1 and COX-2. Cytosolic PGES (cPGES) is constitutively expressed in a wide variety of cells and is functionally linked to COX-1 to promote immediate PGE(2) production. This review highlights the latest understanding of the expression, regulation and funct...Continue Reading

Citations

Nov 28, 2006·Nature Reviews. Cancer·Daniel W Nebert, Timothy P Dalton
Jun 16, 2010·Proceedings of the National Academy of Sciences of the United States of America·Linda VongJohn L Wallace
Jun 4, 2008·Clinical and Experimental Pharmacology & Physiology·Xiaomin YangXiao Han
Apr 7, 2009·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Simo MattilaFrej Stenbäck
Apr 8, 2010·The Journal of Pharmacology and Experimental Therapeutics·Miao WangGarret A FitzGerald
Nov 30, 2012·The Journal of Pharmacology and Experimental Therapeutics·Jianxiong Jiang, Ray Dingledine
Jul 7, 2009·Annual Review of Physiology·Sophie P Farooque, Tak H Lee
Aug 21, 2009·American Journal of Physiology. Renal Physiology·Zhanjun JiaTianxin Yang
Feb 2, 2011·Circulation·Miao WangGarret A Fitzgerald
Sep 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Miao WangGarret A FitzGerald
Nov 6, 2012·Progress in Lipid Research·Alexandra C Kendall, Anna Nicolaou
Feb 18, 2011·Experimental Animals·Makoto Murakami
Jun 13, 2012·Translational Research : the Journal of Laboratory and Clinical Medicine·Noha Ahmed Nasef, Lynnette R Ferguson
Aug 1, 2010·Trends in Cardiovascular Medicine·Miao Wang, Garret A FitzGerald
May 20, 2008·Biochemical and Biophysical Research Communications·N ElanderP Söderkvist
Jun 26, 2009·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Q WuH W Chu
Jan 30, 2007·Journal of Neurochemistry·Akhlaq A FarooquiTahira Farooqui
Aug 19, 2007·Liver International : Official Journal of the International Association for the Study of the Liver·Yasushi TakiiKiyoshi Migita
Dec 18, 2009·Biomedical Chromatography : BMC·Ian A Blair
Feb 3, 2015·IEEE Transactions on Nanobioscience·Lin WuFang-Xiang Wu
Mar 1, 2008·Biochemical and Biophysical Research Communications·Hiromi DaiyasuHiroyuki Toh
Mar 8, 2014·Blood Cells, Molecules & Diseases·Hal E Broxmeyer, Louis M Pelus
Apr 11, 2015·Mediators of Inflammation·Haiping WangRong Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

© 2021 Meta ULC. All rights reserved